Verginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J, Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA, Koumenis C, Busch TM. FLASH proton reirradiation, with or without hypofractionation, reduces
Read More
Verginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J, Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA, Koumenis C, Busch TM. FLASH proton reirradiation, with or without hypofractionation, reduces
Read More
Radiotherapy (RT) is a common treatment for abdominal cancers like pancreatic tumors. Despite advancements in RT delivery, its effectiveness is hindered by the proximity of the radiosensitive intestine.
Despite technological advancements in RT techniques, which enhance tumor targeting precision and minimize incidental cardiac doses, late cardiac toxicity remains a concern.
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor, with a 5-year survival rate of approximately 11%. While RT is used to mitigate tumor recurrence in advanced pancreatic cancer, it frequently leads to severe gastrointestinal side effects.
Despite recent advances in prevention and treatment, pancreatic ductal adenocarcinoma (PDAC) remain highly aggressive and lethal due in part to their complex tumor microenvironment.
Studies over the past decade suggest that ultra-high dose rates, exceeding 40 Gy/s, termed “FLASH” radiotherapy, improve the therapeutic index of radiation therapy (RT) by reducing normal tissue damage while maintaining tumor response compared to conventional RT.